Campus Alert: Find the latest UMMS campus news and resources at umassmed.edu/coronavirus


Print

2019 Press Releases

-Archives-

Jake Kennedy ALS Fund to support research at UMass Medical School

Jake Kennedy ALS Fund to support research at UMass Medical School

Jake and Sparky Kennedy, long known for their generosity as founders of the annual Boston Christmas in the City celebration for thousands of homeless children, are launching a new drive to raise $1 million to support research at UMass Medical School to cure ALS.

Top story: ALS Phase II clinical trial led by Robert Brown shows treatment is safe, well tolerated

Top story: ALS Phase II clinical trial led by Robert Brown shows treatment is safe, well tolerated

A study by Robert H. Brown Jr., MD, DPhil, published in the journal Neurology, shows that a single transplantation of a bone marrow-derived mesenchymal stem cell treatment for amyotrophic lateral sclerosis (ALS) called NurOwn was safe and well tolerated by patients.

Top story: UMass Medical School first in New England for primary care

Top story: UMass Medical School first in New England for primary care

The annual U.S. News & World Report rankings of the best graduate schools names UMass Medical School tops in New England for primary care education among 152 medical schools and 33 schools of osteopathic medicine surveyed by the weekly news magazine in its 2020 edition of the Best Graduate Schools.

Top story: Graduating students are ‘awed and grateful’ at UMass Medical School on Match Day

Top story: Graduating students are ‘awed and grateful’ at UMass Medical School on Match Day

The School of Medicine Class of 2019 celebrated the residency matches of 125 students on Friday, March 15, with family, friends, students and faculty.

UMass Medical School, GE Healthcare Life Sciences to establish viral vector manufacturing facility

UMass Medical School, GE Healthcare Life Sciences to establish viral vector manufacturing facility

UMass Medical School and GE Healthcare Life Sciences will establish a new, large-scale viral vector manufacturing facility, able to provide large quantities of high-quality recombinant adeno-associated virus vectors for preclinical research on the UMMS campus in Worcester.

Michael Volkert and Jonathan Watts awarded BRIDGE grants for innovative research

Michael Volkert and Jonathan Watts awarded BRIDGE grants for innovative research

Two UMass Medical School scientists have been awarded grants from the school’s BRIDGE Fund to advance discoveries into potentially viable commercial therapies for childhood asthma and eye diseases.

Sally Kent named Fuller Foundation Term Chair in Diabetes

Sally Kent named Fuller Foundation Term Chair in Diabetes

Sally C. Kent, PhD, has been named the George F. and Sybil H. Fuller Foundation Term Chair in Diabetes. Dr. Kent studies autoimmune response in type 1 diabetes. 

UMass Medical School, UMass Memorial Medical Center 11th annual Winter Ball raises more than $1.3 million

UMass Medical School, UMass Memorial Medical Center 11th annual Winter Ball raises more than $1.3 million

The 11th annual Winter Ball raised more than $1.3 million to help support the clinical care, education and biomedical research missions of UMass Medical School and UMass Memorial Medical Center.

UMass Medical School improving employment prospects for youth with mental health disabilities

UMass Medical School improving employment prospects for youth with mental health disabilities

Marsha Ellison, PhD, and Maryann Davis, PhD, of the UMMS Transitions to Adulthood Center for Research are consortium partners on a four-year, $4 million grant to establish the National Policy Development Center for Preparing Youth and Young Adults with Disabilities for Employment.

ALS Phase II clinical trial led by Robert Brown shows treatment is safe, well tolerated

ALS Phase II clinical trial led by Robert Brown shows treatment is safe, well tolerated

A study by Robert H. Brown Jr., MD, DPhil, published in the journal Neurology, shows that a single transplantation of a bone marrow-derived mesenchymal stem cell treatment for amyotrophic lateral sclerosis (ALS) called NurOwn was safe and well tolerated by patients.